menu
    • menu
    [{"orgOrder":0,"company":"Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz","sponsor":"Hospital Universitario La Paz | Brighton and Sussex University Hospitals NHS Trust | University of Luebeck | Servicio Vasco de Salud Osakidetza | University of Liverpool | Vest Children\u2019s Hospital | Datteln University Witten-Herdecke | Iuliu Hatieganu Uni","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SPAIN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dobutamine Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz \/ Hospital Universitario La Paz | Brighton and Sussex University Hospitals NHS Trust | University of Luebeck | Servicio Vasco de Salud Osakidetza | University of Liverpool | Vest Children\u2019s Hospital | Datteln University Witten-Herdecke | Iuliu Hatieganu Uni","highestDevelopmentStatusID":"7","companyTruncated":"Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz \/ Hospital Universitario La Paz | Brighton and Sussex University Hospitals NHS Trust | University of Luebeck | Servicio Vasco de Salud Osakidetza | University of Liverpool | Vest Children\u2019s Hospital | Datteln University Witten-Herdecke | Iuliu Hatieganu Uni"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dobutamine Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dobutamine Hydrochloride","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hikma Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hikma Pharmaceuticals \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Dobutamine Hydrochloride

    Menu

    Dobutamine Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Hikma Pharmaceuticals

                            United Kingdom arrow
                            AllPack Indonesia
                            Not Confirmed

                            Hikma Pharmaceuticals

                            United Kingdom arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dobutamine Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hikma Exceeds 150 Injectable Medicines in The US with Launch of Dobutamine Injection, USP

                            Details : Dobutamine injection stimulates heart muscle and improves blood flow by helping the heart pump better, which is used short-term to treat cardiac decompensation due to weakened heart muscle.

                            Product Name : Dobutamine-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 14, 2023

                            Lead Product(s) : Dobutamine Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Northwell Health

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            Northwell Health

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dobutamine Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dobutamine on the Cardiac Conduction System

                            Details : Dobutamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Arrhythmias, Cardiac.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 30, 2020

                            Lead Product(s) : Dobutamine Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dobutamine Hydrochloride

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase I/ Phase II

                            Sponsor : Hospital Universitario La Paz | Brighton and Sussex University Hospitals NHS Trust | University of Luebeck | Servicio Vasco de Salud Osakidetza | University of Liverpool | Vest Children’s Hospital | Datteln University Witten-Herdecke | Iuliu Hatieganu Uni

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dobutamine in the Treatment of Haemodynamic Insufficiency in the Immediate Postnatal Period

                            Details : Dobutamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Shock.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 17, 2017

                            Lead Product(s) : Dobutamine Hydrochloride

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Hospital Universitario La Paz | Brighton and Sussex University Hospitals NHS Trust | University of Luebeck | Servicio Vasco de Salud Osakidetza | University of Liverpool | Vest Children’s Hospital | Datteln University Witten-Herdecke | Iuliu Hatieganu Uni

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth